Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma Editorial

   


Authors: Ladanyi, M.; Sanchez Vega, F.; Zauderer, M.
Title: Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma
Abstract: As trials of immune checkpoint inhibitor (ICI) therapies demonstrate responses in only a minority of pleural mesotheliomas (PlMs) and largely exclude patients with the related peritoneal mesothelioma (PeM), clinicians need predictive biomarkers of response and inclusion of PeM patients in future trials. A new study finds that loss of the deubiquitinase BAP1 in PeM correlates with an inflammatory tumor microenvironment, suggesting that BAP1 status might identify PeM, and possibly PlM, patients who would benefit from ICI therapy. © 2019 The Author(s).
Keywords: unclassified drug; drug efficacy; ipilimumab; ticilimumab; cancer immunotherapy; tumor marker; pleura mesothelioma; peritoneum mesothelioma; rare disease; tumor microenvironment; nivolumab; human; priority journal; article; pembrolizumab; protein bap1
Journal Title: Genome Medicine
Volume: 11
ISSN: 1756-994X
Publisher: Biomed Central Ltd  
Date Published: 2019-03-26
Start Page: 18
Language: English
DOI: 10.1186/s13073-019-0631-0
PUBMED: 30914057
PROVIDER: scopus
PMCID: PMC6436227
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85063458652&doi=10.1186%2fs13073-019-0631-0&partnerID=40&md5=07b4545cb709fd389f114c2f382b76c8
Notes: Article -- Export Date: 1 May 2019 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Marc Ladanyi
    1330 Ladanyi
  2. Marjorie G Zauderer
    189 Zauderer
  3. Francisco Sanchez Vega
    137 Sanchez Vega
Related MSK Work